首页 > 最新文献

Reumatologia最新文献

英文 中文
Higher detectability of amyloid with phenol Congo red compared with alkaline Congo red. 与碱性刚果红相比,苯酚刚果红对淀粉样蛋白的检出率更高。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-06 DOI: 10.5114/reum/192390
Marta Legatowicz-Koprowska, Justyna Szczygieł, Małgorzata Mańczak, Ewa Walczak

Introduction: Amyloidosis is a heterogeneous group of conditions associated with tissue deposition of insoluble abnormal proteins that damage vital organs. Early diagnosis, when the deposits are minimal, determines the prognosis and requires histological confirmation. The commonly adopted gold standard technique is alkaline Congo red (ACR) staining, though its sensitivity is limited. There is a need for a simple and inexpensive screening method offering a better chance of detecting minimal amyloid deposits. The aim of this study was to compare amyloid detectability with ACR and phenol Congo red (PHCR) staining techniques for early detection of minimal deposits.

Material and methods: We assessed 452 tissue specimens (including adipose tissue, gastrointestinal mucosa, labial salivary gland, myocardium, and bone marrow) from 425 patients with clinically suspected systemic or local amyloidosis, which had been sent to the Pathology Laboratory of the National Institute of Geriatrics, Rheumatology and Rehabilitation in Warsaw. Adjacent sections from each specimen were stained with ACR and PHCR. If amyloid was detected, immunohistochemical typing was conducted. The consistency of the two staining methods was expressed as Cohen's κ coefficient.

Results: A total of 169 tissue specimens (37%) yielded positive readings, with 93 cases ACR(+) and PHCR(+); 75 cases ACR(-) and PHCR(+), and 1 case ACR(+) and PHCR(-). The percentage agreement between the staining methods was 83%, with the Cohen's κ coefficient value of 0.60 (95% CI: 0.52-0.69), which corresponds to moderate agreement according to Fleiss. Additional immunohistochemical amyloid typing, conducted in ACR(-) and PHCR(+) specimens, yielded conclusive results in 82% of cases.

Conclusions: The use of PHCR staining as a screening method in suspected amyloidosis improves amyloid (light chain, transthyretin, and amyloid A protein) detectability in various tissues. The PHCR staining specificity should be verified via electron microscopy and/or mass spectrometry.

简介:淀粉样变性是一种异质性疾病,与不溶性异常蛋白的组织沉积有关,损害重要器官。早期诊断,当沉积物是最小的,决定预后,需要组织学证实。通常采用的金标准技术是碱性刚果红(ACR)染色,尽管其灵敏度有限。需要一种简单而廉价的筛查方法,以提供更好的机会检测最小的淀粉样蛋白沉积。本研究的目的是比较淀粉样蛋白检测与ACR和苯酚刚果红(PHCR)染色技术早期检测微量沉积物。材料和方法:我们评估了425例临床疑似全身性或局部淀粉样变性患者的452份组织标本(包括脂肪组织、胃肠黏膜、唇唾液腺、心肌和骨髓),这些标本已送往华沙国立老年病学、风湿病和康复研究所病理实验室。每个标本的相邻切片用ACR和PHCR染色。如果检测到淀粉样蛋白,则进行免疫组织化学分型。两种染色方法的一致性用Cohen’s κ系数表示。结果:169例组织标本(37%)呈阳性,其中ACR(+)和PHCR(+) 93例;ACR(-)和PHCR(+) 75例,ACR(+)和PHCR(-) 1例。两种染色方法的一致性百分比为83%,Cohen's κ系数值为0.60 (95% CI: 0.52-0.69),根据Fleiss,这对应于中度一致性。在ACR(-)和PHCR(+)标本中进行的额外免疫组织化学淀粉样蛋白分型在82%的病例中得出了结论性结果。结论:PHCR染色作为疑似淀粉样变性的筛查方法可提高各种组织中淀粉样蛋白(轻链、转甲状腺素和淀粉样蛋白a蛋白)的检出率。应通过电子显微镜和/或质谱法验证PHCR染色的特异性。
{"title":"Higher detectability of amyloid with phenol Congo red compared with alkaline Congo red.","authors":"Marta Legatowicz-Koprowska, Justyna Szczygieł, Małgorzata Mańczak, Ewa Walczak","doi":"10.5114/reum/192390","DOIUrl":"10.5114/reum/192390","url":null,"abstract":"<p><strong>Introduction: </strong>Amyloidosis is a heterogeneous group of conditions associated with tissue deposition of insoluble abnormal proteins that damage vital organs. Early diagnosis, when the deposits are minimal, determines the prognosis and requires histological confirmation. The commonly adopted gold standard technique is alkaline Congo red (ACR) staining, though its sensitivity is limited. There is a need for a simple and inexpensive screening method offering a better chance of detecting minimal amyloid deposits. The aim of this study was to compare amyloid detectability with ACR and phenol Congo red (PHCR) staining techniques for early detection of minimal deposits.</p><p><strong>Material and methods: </strong>We assessed 452 tissue specimens (including adipose tissue, gastrointestinal mucosa, labial salivary gland, myocardium, and bone marrow) from 425 patients with clinically suspected systemic or local amyloidosis, which had been sent to the Pathology Laboratory of the National Institute of Geriatrics, Rheumatology and Rehabilitation in Warsaw. Adjacent sections from each specimen were stained with ACR and PHCR. If amyloid was detected, immunohistochemical typing was conducted. The consistency of the two staining methods was expressed as Cohen's κ coefficient.</p><p><strong>Results: </strong>A total of 169 tissue specimens (37%) yielded positive readings, with 93 cases ACR(+) and PHCR(+); 75 cases ACR(-) and PHCR(+), and 1 case ACR(+) and PHCR(-). The percentage agreement between the staining methods was 83%, with the Cohen's κ coefficient value of 0.60 (95% CI: 0.52-0.69), which corresponds to moderate agreement according to Fleiss. Additional immunohistochemical amyloid typing, conducted in ACR(-) and PHCR(+) specimens, yielded conclusive results in 82% of cases.</p><p><strong>Conclusions: </strong>The use of PHCR staining as a screening method in suspected amyloidosis improves amyloid (light chain, transthyretin, and amyloid A protein) detectability in various tissues. The PHCR staining specificity should be verified via electron microscopy and/or mass spectrometry.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"338-345"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical cyclosporine A in the management of dry eye disease in Sjögren's syndrome.
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-12-19 DOI: 10.5114/reum/197334
Nora Majtánová, Veronika Kurilová, Petr Kolář
{"title":"Topical cyclosporine A in the management of dry eye disease in Sjögren's syndrome.","authors":"Nora Majtánová, Veronika Kurilová, Petr Kolář","doi":"10.5114/reum/197334","DOIUrl":"10.5114/reum/197334","url":null,"abstract":"","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 6","pages":"395-397"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A variety of clinical presentations of eosinophilic granulomatosis with polyangiitis: a comprehensive review.
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-12-24 DOI: 10.5114/reum/196141
Agata Sebastian, Joanna Kosałka-Węgiel

Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by eosinophilic granulomatous vasculitis. Typical symptoms include late-onset bronchial asthma and blood and tissue eosinophilia. In addition to these characteristic symptoms, EGPA can affect important organs such as the skin, kidneys, heart, sinuses, gastrointestinal tract, and nervous system. Given the variability of the clinical presentation, EGPA is challenging to diagnose. Furthermore, EGPA often occurs in phases, with clinical manifestations and pathological findings varying depending on the affected anatomic site and stage of disease.

Material and methods: The authors reviewed the SCOPUS, MEDLINE, and PubMed medical databases to prepare an overview of the clinical manifestations and diagnosis for EGPA.

Results: This comprehensive review examines the current knowledge on the clinical course of EGPA, diagnostic options and prognostic factors.

Conclusions: We highlight the diverse organ involvement observed in EGPA, particularly in association with eosinophilic and vasculitic manifestations. Our findings underscore the importance of anti-neutrophil cytoplasm antibody status as a potential key factor influencing disease presentation.

{"title":"A variety of clinical presentations of eosinophilic granulomatosis with polyangiitis: a comprehensive review.","authors":"Agata Sebastian, Joanna Kosałka-Węgiel","doi":"10.5114/reum/196141","DOIUrl":"10.5114/reum/196141","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by eosinophilic granulomatous vasculitis. Typical symptoms include late-onset bronchial asthma and blood and tissue eosinophilia. In addition to these characteristic symptoms, EGPA can affect important organs such as the skin, kidneys, heart, sinuses, gastrointestinal tract, and nervous system. Given the variability of the clinical presentation, EGPA is challenging to diagnose. Furthermore, EGPA often occurs in phases, with clinical manifestations and pathological findings varying depending on the affected anatomic site and stage of disease.</p><p><strong>Material and methods: </strong>The authors reviewed the SCOPUS, MEDLINE, and PubMed medical databases to prepare an overview of the clinical manifestations and diagnosis for EGPA.</p><p><strong>Results: </strong>This comprehensive review examines the current knowledge on the clinical course of EGPA, diagnostic options and prognostic factors.</p><p><strong>Conclusions: </strong>We highlight the diverse organ involvement observed in EGPA, particularly in association with eosinophilic and vasculitic manifestations. Our findings underscore the importance of anti-neutrophil cytoplasm antibody status as a potential key factor influencing disease presentation.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 6","pages":"456-465"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional disorders and nutrition-related conditions: an underestimated clinical problem in systemic sclerosis. 营养失调和营养相关疾病:系统性硬化症中一个被低估的临床问题。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-09 DOI: 10.5114/reum/194035
Anna Wojteczek, Michał Chmielewski, Zbigniew Zdrojewski

Nutritional disorders are significant but often underestimated complications in patients with systemic sclerosis (SSc). The most prevalent nutritional disorders in SSc are malnutrition, affecting up to 62.5% of patients, and sarcopenia, with a frequency of up to 42%. Thus, clinical vigilance is recommended for the detection of eating disorders in SSc patients, particularly those with gastrointestinal involvement, cardiopulmonary complications, an advanced disease stage, and high disease activity. Nutritional treatment should be carefully tailored to the patients' clinical condition to ensure that it effectively addresses their specific needs. Studies focusing on enteral nutrition in SSc patients demonstrate its effectiveness in stabilizing or improving nutritional status in malnourished patients. In severe cases, parenteral nutrition offers viable options to support patient health. The findings highlight the importance of early nutritional assessment and intervention in improving patient outcomes and suggest that individualized nutritional therapy can be a critical component of comprehensive care for SSc patients.

营养失调是系统性硬化症(SSc)患者的重要但常被低估的并发症。SSc中最常见的营养失调是营养不良,影响高达62.5%的患者,以及肌肉减少症,发生率高达42%。因此,建议临床警惕SSc患者的饮食失调,特别是那些有胃肠道受累、心肺并发症、疾病晚期和疾病活动度高的患者。营养治疗应根据患者的临床情况精心定制,以确保有效地满足患者的特殊需求。关注肠内营养在SSc患者中的研究表明其在稳定或改善营养不良患者的营养状况方面是有效的。在严重的情况下,肠外营养为支持患者健康提供了可行的选择。研究结果强调了早期营养评估和干预对改善患者预后的重要性,并建议个体化营养治疗可以成为SSc患者综合护理的关键组成部分。
{"title":"Nutritional disorders and nutrition-related conditions: an underestimated clinical problem in systemic sclerosis.","authors":"Anna Wojteczek, Michał Chmielewski, Zbigniew Zdrojewski","doi":"10.5114/reum/194035","DOIUrl":"10.5114/reum/194035","url":null,"abstract":"<p><p>Nutritional disorders are significant but often underestimated complications in patients with systemic sclerosis (SSc). The most prevalent nutritional disorders in SSc are malnutrition, affecting up to 62.5% of patients, and sarcopenia, with a frequency of up to 42%. Thus, clinical vigilance is recommended for the detection of eating disorders in SSc patients, particularly those with gastrointestinal involvement, cardiopulmonary complications, an advanced disease stage, and high disease activity. Nutritional treatment should be carefully tailored to the patients' clinical condition to ensure that it effectively addresses their specific needs. Studies focusing on enteral nutrition in SSc patients demonstrate its effectiveness in stabilizing or improving nutritional status in malnourished patients. In severe cases, parenteral nutrition offers viable options to support patient health. The findings highlight the importance of early nutritional assessment and intervention in improving patient outcomes and suggest that individualized nutritional therapy can be a critical component of comprehensive care for SSc patients.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"368-380"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimal disease activity and associated factors in patients with psoriatic arthritis: cross-sectional study from a single center. 银屑病关节炎患者的最小疾病活动度及相关因素:来自一个中心的横断面研究。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-06 DOI: 10.5114/reum/194595
Murat Bektas, Berk Çelik, Burak İnce, Yasemin Yalçınkaya, Bahar Artım Esen, Ahmet Gül, Murat İnanç

Introduction: Psoriatic arthritis (PsA) is a heterogeneous disease with various manifestations such as dactylitis, enthesitis, spondylitis, and skin involvement. Minimal disease activity (MDA) has been successfully used in daily clinical practice and is considered a reasonable treatment target in patients with PsA. In this study, we aimed to evaluate the MDA status and associated factors in patients with PsA in our tertiary referral clinic.

Material and methods: This cross-sectional study included patients who met the CASPAR classification criteria and had at least 6 months of follow-up data between 2001 and 2021. Patients who met at least 5 of 7 criteria (tender joint count ≤ 1/68, swollen joint count ≤ 1/66, Psoriasis Area Severity Index [PASI] ≤ 1, Visual Analogue Scale [VAS] ≤ 15, patient global VAS ≤ 20, Health Assessment Questionnaire-Disability Index [HAQ-DI] ≤ 0.5, and enthesitis number ≤ 1) were considered to achieve MDA.

Results: Data from 172 patients (61% female) were analyzed and included in the study. While most patients had polyarticular involvement (33.7%), mono-oligoarthritis was present in 30.2%, mixed type in 26.2%, isolated distal interphalangeal arthritis in 5.8%, isolated spondylitis in 2.9%, and arthritis mutilans in 1.2%. Overall, 95 (55.2%) of the patients were observed at MDA, which was lower in tumor necrosis factor inhibitor (TNFi) users compared to only conventional synthetic disease-modifying antirheumatic drug users. In univariate analysis, MDA was associated with higher patient age, longer psoriasis duration, late-onset PsA, and continued use of first TNFi. In multivariate analysis, higher patient age, late-onset PsA, and higher continuation rate of first TNFi were associated with MDA.

Conclusions: In the study, more than half of our patients achieved MDA status. A higher MDA rate was associated with a higher continuation rate at first-line TNFi treatment. The relatively large population who could not reach MDA status in our study indicates an unmet need for monitoring and treatment of PsA.

导言银屑病关节炎(PsA)是一种异质性疾病,有各种表现,如趾骨炎、趾关节炎、脊柱炎和皮肤受累。最小疾病活动度(MDA)已成功应用于日常临床实践,并被认为是 PsA 患者的合理治疗目标。在这项研究中,我们旨在评估我们三级转诊诊所中PsA患者的MDA状况及相关因素:这项横断面研究纳入了符合 CASPAR 分类标准且在 2001 年至 2021 年期间至少有 6 个月随访数据的患者。符合 7 项标准中至少 5 项标准(关节触痛计数≤1/68、关节肿胀计数≤1/66、银屑病面积严重程度指数[PASI]≤1、视觉模拟量表[VAS]≤15、患者总体 VAS≤20、健康评估问卷-残疾指数[HAQ-DI]≤0.5、关节内炎数目≤1)的患者被视为达到 MDA:研究分析并纳入了 172 名患者(61% 为女性)的数据。大多数患者为多关节受累(33.7%),单侧孤立性关节炎占 30.2%,混合型占 26.2%,孤立性远端指间关节炎占 5.8%,孤立性脊柱炎占 2.9%,残缺性关节炎占 1.2%。总体而言,有95名(55.2%)患者被观察到有MDA,与仅使用传统合成改善病情抗风湿药物的患者相比,肿瘤坏死因子抑制剂(TNFi)使用者的MDA较低。在单变量分析中,MDA 与患者年龄较大、银屑病病程较长、晚发 PsA 以及持续使用第一种 TNFi 药物有关。在多变量分析中,患者年龄越大、PsA发病时间越晚、继续使用第一种TNFi的比例越高,均与MDA有关:结论:在这项研究中,半数以上的患者达到了MDA状态。结论:在本研究中,半数以上的患者达到了MDA状态,较高的MDA率与较高的一线TNFi治疗持续率相关。在我们的研究中,未能达到MDA状态的人群相对较多,这表明PsA的监测和治疗需求尚未得到满足。
{"title":"Minimal disease activity and associated factors in patients with psoriatic arthritis: cross-sectional study from a single center.","authors":"Murat Bektas, Berk Çelik, Burak İnce, Yasemin Yalçınkaya, Bahar Artım Esen, Ahmet Gül, Murat İnanç","doi":"10.5114/reum/194595","DOIUrl":"10.5114/reum/194595","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriatic arthritis (PsA) is a heterogeneous disease with various manifestations such as dactylitis, enthesitis, spondylitis, and skin involvement. Minimal disease activity (MDA) has been successfully used in daily clinical practice and is considered a reasonable treatment target in patients with PsA. In this study, we aimed to evaluate the MDA status and associated factors in patients with PsA in our tertiary referral clinic.</p><p><strong>Material and methods: </strong>This cross-sectional study included patients who met the CASPAR classification criteria and had at least 6 months of follow-up data between 2001 and 2021. Patients who met at least 5 of 7 criteria (tender joint count ≤ 1/68, swollen joint count ≤ 1/66, Psoriasis Area Severity Index [PASI] ≤ 1, Visual Analogue Scale [VAS] ≤ 15, patient global VAS ≤ 20, Health Assessment Questionnaire-Disability Index [HAQ-DI] ≤ 0.5, and enthesitis number ≤ 1) were considered to achieve MDA.</p><p><strong>Results: </strong>Data from 172 patients (61% female) were analyzed and included in the study. While most patients had polyarticular involvement (33.7%), mono-oligoarthritis was present in 30.2%, mixed type in 26.2%, isolated distal interphalangeal arthritis in 5.8%, isolated spondylitis in 2.9%, and arthritis mutilans in 1.2%. Overall, 95 (55.2%) of the patients were observed at MDA, which was lower in tumor necrosis factor inhibitor (TNFi) users compared to only conventional synthetic disease-modifying antirheumatic drug users. In univariate analysis, MDA was associated with higher patient age, longer psoriasis duration, late-onset PsA, and continued use of first TNFi. In multivariate analysis, higher patient age, late-onset PsA, and higher continuation rate of first TNFi were associated with MDA.</p><p><strong>Conclusions: </strong>In the study, more than half of our patients achieved MDA status. A higher MDA rate was associated with a higher continuation rate at first-line TNFi treatment. The relatively large population who could not reach MDA status in our study indicates an unmet need for monitoring and treatment of PsA.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"330-337"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential biomarkers in Behçet's disease: monocyte, neutrophil, platelet, and C-reactive protein to albumin ratios. 白塞氏病的潜在生物标志物:单核细胞、中性粒细胞、血小板和 C 反应蛋白与白蛋白的比率。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-06 DOI: 10.5114/reum/192391
Mestan Sahin, Cansu Celin Karakose, Meltem Alkan Melikoglu

Introduction: The objective of this cross-sectional study was to evaluate the monocyte to albumin ratio (MAR), neutrophil to albumin ratio (NAR), platelet to albumin ratio (PAR), and C-reactive protein to albumin ratio (CAR) as potential biomarkers for disease activity in patients with Behçet's disease (BD).

Material and methods: Both BD cases and healthy controls were enrolled in this study. Demographic characteristics, disease duration, and current medications were recorded for all participants. The BD Current Activity Form (BDCAF) was utilized to assess the activity of BD. Additionally, erythrocyte sedimentation rate, CRP, and serum albumin levels were measured. The MAR, NAR, PAR, and CAR were compared between the two groups. Correlation analysis and receiver operating characteristic curves (ROC) were employed to establish cut-off points for these biomarkers.

Results: In the study, both BD cases and 45 controls were included, totaling 90 participants. Significant differences were observed in the mean ±SD values of ESR, MAR, PAR, CAR, and albumin between the BD cases and controls (p = 0.008, p = 0.009, p = 0.029, p = 0.034, p = 0.006, respectively). However, despite these differences, no significant correlation was detected between BDCAF and the parameters under investigation. The cut-off point was determined as 150.59 (sensitivity 46.67%, specificity 82.22%, p = 0.008, AUC = 0.655) for MAR; as 62,013.73 (sensitivity 60.00%, specificity 66.67%, p = 0.03, AUC = 0.629) for PAR; and as 1.16 (sensitivity 35.56%, specificity of 95.567%, p = 0.03, AUC = 0.629) for CAR. The results were not able to define any cut-off points for active-inactive BD.

Conclusions: Significantly higher levels of MAR, PAR, and CAR were observed in patients with BD than controls. Monocyte to albumin ratio, PAR, and CAR were notably elevated in patients with active BD. This finding suggests that these parameters possess discriminative ability and could potentially serve as biomarkers to aid in the clinical evaluation of BD.

本横断研究的目的是评估单核细胞与白蛋白比率(MAR)、中性粒细胞与白蛋白比率(NAR)、血小板与白蛋白比率(PAR)和c反应蛋白与白蛋白比率(CAR)作为behet病(BD)患者疾病活动性的潜在生物标志物。材料和方法:本研究纳入了BD病例和健康对照。记录所有参与者的人口统计学特征、病程和当前用药情况。采用BD电流活性表(BDCAF)评估BD活性。此外,还测量红细胞沉降率、CRP和血清白蛋白水平。比较两组患者的MAR、NAR、PAR、CAR。采用相关分析和受试者工作特征曲线(ROC)建立这些生物标志物的分界点。结果:本研究纳入了2例BD病例和45例对照,共90例受试者。BD组与对照组ESR、MAR、PAR、CAR、白蛋白的平均±SD值差异有统计学意义(p = 0.008, p = 0.009, p = 0.029, p = 0.034, p = 0.006)。然而,尽管存在这些差异,但在BDCAF和所研究的参数之间没有发现显著的相关性。MAR的截断点为150.59(敏感性46.67%,特异性82.22%,p = 0.008, AUC = 0.655);为62,013.73(敏感性60.00%,特异性66.67%,p = 0.03, AUC = 0.629);CAR为1.16(敏感性35.56%,特异性95.567%,p = 0.03, AUC = 0.629)。研究结果无法定义活跃-非活跃BD的分界点。结论:BD患者的MAR、PAR和CAR水平明显高于对照组。单核细胞/白蛋白比、PAR和CAR在活动性双相障碍患者中显著升高。这一发现表明,这些参数具有鉴别能力,可能作为生物标志物,帮助双相障碍的临床评估。
{"title":"Potential biomarkers in Behçet's disease: monocyte, neutrophil, platelet, and C-reactive protein to albumin ratios.","authors":"Mestan Sahin, Cansu Celin Karakose, Meltem Alkan Melikoglu","doi":"10.5114/reum/192391","DOIUrl":"10.5114/reum/192391","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this cross-sectional study was to evaluate the monocyte to albumin ratio (MAR), neutrophil to albumin ratio (NAR), platelet to albumin ratio (PAR), and C-reactive protein to albumin ratio (CAR) as potential biomarkers for disease activity in patients with Behçet's disease (BD).</p><p><strong>Material and methods: </strong>Both BD cases and healthy controls were enrolled in this study. Demographic characteristics, disease duration, and current medications were recorded for all participants. The BD Current Activity Form (BDCAF) was utilized to assess the activity of BD. Additionally, erythrocyte sedimentation rate, CRP, and serum albumin levels were measured. The MAR, NAR, PAR, and CAR were compared between the two groups. Correlation analysis and receiver operating characteristic curves (ROC) were employed to establish cut-off points for these biomarkers.</p><p><strong>Results: </strong>In the study, both BD cases and 45 controls were included, totaling 90 participants. Significant differences were observed in the mean ±SD values of ESR, MAR, PAR, CAR, and albumin between the BD cases and controls (<i>p</i> = 0.008, <i>p</i> = 0.009, <i>p</i> = 0.029, <i>p</i> = 0.034, <i>p</i> = 0.006, respectively). However, despite these differences, no significant correlation was detected between BDCAF and the parameters under investigation. The cut-off point was determined as 150.59 (sensitivity 46.67%, specificity 82.22%, <i>p</i> = 0.008, AUC = 0.655) for MAR; as 62,013.73 (sensitivity 60.00%, specificity 66.67%, <i>p</i> = 0.03, AUC = 0.629) for PAR; and as 1.16 (sensitivity 35.56%, specificity of 95.567%, <i>p</i> = 0.03, AUC = 0.629) for CAR. The results were not able to define any cut-off points for active-inactive BD.</p><p><strong>Conclusions: </strong>Significantly higher levels of MAR, PAR, and CAR were observed in patients with BD than controls. Monocyte to albumin ratio, PAR, and CAR were notably elevated in patients with active BD. This finding suggests that these parameters possess discriminative ability and could potentially serve as biomarkers to aid in the clinical evaluation of BD.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"308-313"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patterns and prevalence of psychiatric morbidity among individuals with rheumatoid arthritis. 类风湿性关节炎患者的精神病发病模式和发病率。
Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-04-30 DOI: 10.5114/reum/186975
Ajaz Kariem Khan, Junaid Nabi, Ashaq Hussain Parrey, Prasan Deep Rath, Sanan Lone

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects the joints, causing inflammation, pain, and potential joint damage. Patients with RA are at high risk of developing psychiatric morbidity; it is important to recognize these psychiatric manifestations. The relationship between psychiatric symptoms and RA is complex and can involve various factors, including the impact of chronic pain, inflammation, medications, and the overall burden of managing a chronic illness.Aim of the study was to systematically investigate and analyze the patterns and prevalence of psychiatric morbidity among individuals diagnosed with RA, with the aim of identifying common mental health conditions, understanding the interplay between RA and psychiatric disorders, and providing valuable insights for improved holistic patient care.

Material and methods: This was a prospective, observational cross-sectional study conducted over a period of three years in patients with RA. Psychiatric morbidity was assessed using International Classification of Diseases-10 criteria and Mini-Plus by dedicated psychiatrists. The diagnosis of RA was confirmed using the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) diagnostic criteria for RA and the disease activity was calculated by Disease Activity Score with 28-joint count (DAS28) using the calculator from the RheumaHelper application. The data were analyzed using SPSS, version 23.0.

Results: A total of 1,000 patients with RA were included in this study. Nearly two-thirds of the patients were female (64.8%). The majority of patients belonged to the age group of 41 to 54 years. Total 47.5% of the patients were unemployed, 27.0% were salaried, 19.0% were businessman, while 6.5% of the patients were students. More than half of the patients (53.2%) had moderate disease activity. Major depressive disorder was the most commonly observed comorbidity (41.0%), followed by somatoform disorder (28.5%), and generalized anxiety disorder was found in 13.5%. No psychiatric manifestations were found in 17% of studied individuals.

Conclusions: Psychiatric morbidity is associated with RA and there is a need for psychiatric services to be made available to these patients.

简介类风湿性关节炎(RA)是一种影响关节的慢性自身免疫性疾病,会引起炎症、疼痛和潜在的关节损伤。类风湿关节炎患者是精神疾病的高危人群,因此识别这些精神症状表现非常重要。精神症状与RA之间的关系很复杂,可能涉及多种因素,包括慢性疼痛、炎症、药物和慢性病管理总体负担的影响。该研究旨在系统调查和分析被诊断为RA患者的精神疾病发病模式和患病率,以确定常见的精神健康状况,了解RA与精神疾病之间的相互作用,并为改善患者的整体护理提供有价值的见解:这是一项为期三年的前瞻性横断面观察研究,研究对象为RA患者。精神疾病发病率由专职精神科医生根据《国际疾病分类-10》标准和 Mini-Plus 进行评估。RA诊断采用2010年美国风湿病学会/欧洲风湿病学协会联盟(ACR/EULAR)的RA诊断标准进行确诊,疾病活动度采用RheumaHelper应用程序中的计算器,以28个关节计数的疾病活动度评分(DAS28)进行计算。数据使用 SPSS 23.0 版进行分析:本研究共纳入了 1,000 名 RA 患者。近三分之二的患者为女性(64.8%)。大多数患者的年龄在 41 至 54 岁之间。47.5%的患者为失业者,27.0%为受薪者,19.0%为商人,6.5%为学生。超过一半的患者(53.2%)有中度疾病活动。重度抑郁症是最常见的合并症(41.0%),其次是躯体形式障碍(28.5%),13.5%的患者患有广泛性焦虑症。17%的受试者未发现任何精神症状:结论:精神疾病的发病率与 RA 有关,有必要为这些患者提供精神科服务。
{"title":"Patterns and prevalence of psychiatric morbidity among individuals with rheumatoid arthritis.","authors":"Ajaz Kariem Khan, Junaid Nabi, Ashaq Hussain Parrey, Prasan Deep Rath, Sanan Lone","doi":"10.5114/reum/186975","DOIUrl":"10.5114/reum/186975","url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects the joints, causing inflammation, pain, and potential joint damage. Patients with RA are at high risk of developing psychiatric morbidity; it is important to recognize these psychiatric manifestations. The relationship between psychiatric symptoms and RA is complex and can involve various factors, including the impact of chronic pain, inflammation, medications, and the overall burden of managing a chronic illness.Aim of the study was to systematically investigate and analyze the patterns and prevalence of psychiatric morbidity among individuals diagnosed with RA, with the aim of identifying common mental health conditions, understanding the interplay between RA and psychiatric disorders, and providing valuable insights for improved holistic patient care.</p><p><strong>Material and methods: </strong>This was a prospective, observational cross-sectional study conducted over a period of three years in patients with RA. Psychiatric morbidity was assessed using International Classification of Diseases-10 criteria and Mini-Plus by dedicated psychiatrists. The diagnosis of RA was confirmed using the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) diagnostic criteria for RA and the disease activity was calculated by Disease Activity Score with 28-joint count (DAS28) using the calculator from the RheumaHelper application. The data were analyzed using SPSS, version 23.0.</p><p><strong>Results: </strong>A total of 1,000 patients with RA were included in this study. Nearly two-thirds of the patients were female (64.8%). The majority of patients belonged to the age group of 41 to 54 years. Total 47.5% of the patients were unemployed, 27.0% were salaried, 19.0% were businessman, while 6.5% of the patients were students. More than half of the patients (53.2%) had moderate disease activity. Major depressive disorder was the most commonly observed comorbidity (41.0%), followed by somatoform disorder (28.5%), and generalized anxiety disorder was found in 13.5%. No psychiatric manifestations were found in 17% of studied individuals.</p><p><strong>Conclusions: </strong>Psychiatric morbidity is associated with RA and there is a need for psychiatric services to be made available to these patients.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 2","pages":"115-120"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11114128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141155351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study. 生物制剂与JAK-STAT抑制剂治疗重度类风湿关节炎的疗效比较。扩展研究。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-09 DOI: 10.5114/reum/194686
Małgorzata Wisłowska

Introduction: This study compared treatment with biologic agents and Janus kinase inhibitors (JAKi) in combination with methotrexate (MTX) for rheumatoid arthritis (RA) in a real-world setting at a large center in Poland. There is a persistent shortage of such studies, and illustrating the switching of medications in search of a suitable way of treatment for a given patient is a crucial step towards future personalized therapy.

Aim of the study: This study is an extension of the initial work published in 2022 in Reumatologia, with the addition of an analysis of patients treated with upadacitinib. The study compared the effectiveness and side effects after treatment of biological disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) in combination with MTX.

Materials and methods: A total of 130 patients with active severe RA (Disease Activity Score for 28 joints based on the erythrocyte sedimentation rate [DAS28(ESR)] value > 5.1) were treated at the Rheumatologic Outpatients Department of the Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland between January 2010 and September 2021. All patients were treated with MTX 25 mg per week. They were divided into two groups: group I (80 patients) treated with biologic agents, and group II (50 patients) treated with JAKi. Assessment of DAS28(ESR) and Simplified Disease Activity Index (SDAI) and analysis of Boolean criteria for remission were performed. Remission or low disease activity, switching between drugs and adverse events were assessed and compared between studied groups.

Results: Patients treated with tsDMARDs had previously used a higher number of conventional synthetic DMARDs (csDMARDs) and bDMARDs compared to those treated with bDMARDs. However, they achieved lower SDAI and assessment of disease activity using Visual Analogue Scale (VAS) values, and a higher proportion of patients achieved Boolean criteria for remission after treatment.

Conclusions: The results of treatment with JAKi were successful, but the potential side effects indicate that this treatment may not be equally suitable for all RA patients.

简介:在波兰的一个大型研究中心,本研究比较了生物制剂和Janus激酶抑制剂(JAKi)联合甲氨蝶呤(MTX)治疗类风湿性关节炎(RA)的效果。这类研究一直缺乏,说明为寻找适合特定患者的治疗方法而转换药物是迈向未来个性化治疗的关键一步。研究目的:该研究是2022年在《风湿病学》(Reumatologia)上发表的初始工作的延伸,增加了对upadacitinib治疗的患者的分析。该研究比较了生物疾病修饰抗风湿药物(bDMARDs)和靶向合成抗风湿药物(tsDMARDs)联合MTX治疗后的疗效和副作用。材料和方法:2010年1月至2021年9月,共有130名活动性重度RA患者(基于红细胞沉降率[DAS28(ESR)]值> 5.1的28个关节疾病活动评分)在波兰华沙内政部和行政部中心临床医院风湿病门诊部接受治疗。所有患者均接受MTX 25mg /周治疗。他们被分为两组:I组(80例)使用生物制剂治疗,II组(50例)使用JAKi治疗。评估DAS28(ESR)和简化疾病活动指数(SDAI),并分析布尔缓解标准。评估缓解或低疾病活动度、药物切换和不良事件,并在研究组之间进行比较。结果:与接受bDMARDs治疗的患者相比,接受tsDMARDs治疗的患者先前使用了更多的常规合成DMARDs (csDMARDs)和bDMARDs。然而,他们获得了较低的SDAI和使用视觉模拟量表(VAS)评估疾病活动性的值,并且更高比例的患者在治疗后达到布尔缓解标准。结论:JAKi治疗的结果是成功的,但潜在的副作用表明,这种治疗可能并不同样适用于所有RA患者。
{"title":"Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study.","authors":"Małgorzata Wisłowska","doi":"10.5114/reum/194686","DOIUrl":"10.5114/reum/194686","url":null,"abstract":"<p><strong>Introduction: </strong>This study compared treatment with biologic agents and Janus kinase inhibitors (JAKi) in combination with methotrexate (MTX) for rheumatoid arthritis (RA) in a real-world setting at a large center in Poland. There is a persistent shortage of such studies, and illustrating the switching of medications in search of a suitable way of treatment for a given patient is a crucial step towards future personalized therapy.</p><p><strong>Aim of the study: </strong>This study is an extension of the initial work published in 2022 in <i>Reumatologia</i>, with the addition of an analysis of patients treated with upadacitinib. The study compared the effectiveness and side effects after treatment of biological disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) in combination with MTX.</p><p><strong>Materials and methods: </strong>A total of 130 patients with active severe RA (Disease Activity Score for 28 joints based on the erythrocyte sedimentation rate [DAS28(ESR)] value > 5.1) were treated at the Rheumatologic Outpatients Department of the Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland between January 2010 and September 2021. All patients were treated with MTX 25 mg per week. They were divided into two groups: group I (80 patients) treated with biologic agents, and group II (50 patients) treated with JAKi. Assessment of DAS28(ESR) and Simplified Disease Activity Index (SDAI) and analysis of Boolean criteria for remission were performed. Remission or low disease activity, switching between drugs and adverse events were assessed and compared between studied groups.</p><p><strong>Results: </strong>Patients treated with tsDMARDs had previously used a higher number of conventional synthetic DMARDs (csDMARDs) and bDMARDs compared to those treated with bDMARDs. However, they achieved lower SDAI and assessment of disease activity using Visual Analogue Scale (VAS) values, and a higher proportion of patients achieved Boolean criteria for remission after treatment.</p><p><strong>Conclusions: </strong>The results of treatment with JAKi were successful, but the potential side effects indicate that this treatment may not be equally suitable for all RA patients.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"322-329"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Automatic assessment of nailfold capillaroscopy software: a pilot study. 甲襞毛细血管镜软件的自动评估:一项试点研究。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-09 DOI: 10.5114/reum/194040
Olga Elżbieta Brzezińska, Krzysztof Andrzej Rychlicki-Kicior, Joanna Samanta Makowska

Introduction: Capillaroscopy is a simple method of nailfold capillary imaging, used to diagnose diseases from the systemic sclerosis spectrum. However, the assessment of the capillary image is time-consuming and subjective. This makes it difficult to use for a detailed comparison of studies assessed by various physicians. This pilot study aimed to validate software used for automatic capillary counting and image classification as normal or pathological.

Material and methods: The study was based on the assessment of 200 capillaroscopic images obtained from patients suffering from systemic sclerosis or scleroderma spectrum diseases and healthy people. Dinolite MEDL4N Pro was used to perform capillaroscopy. Each image was analysed manually and described using working software. The neural network was trained using the fast.ai library (based on PyTorch). The ResNet-34 deep residual neural network was chosen; 10-fold cross-validation with the validation and test set was performed, using the Darknet-YoloV3 state of the art neural network in a GPU-optimized (P5000 GPU) environment. For the calculation of 1 mm capillaries, an additional detection mechanism was designed.

Results: The results obtained under neural network training were compared to the results obtained in manual analysis. The sensitivity of the automatic tool relative to manual assessment in classification of correct vs. pathological images was 89.0%, specificity 89.4% for the training group, in validation 89.0% and 86.9% respectively. For the average number of capillaries in 1 mm the precision of real images detected within the region of interest was 96.48%.

Conclusions: The pilot software for fully automatic capillaroscopic image assessment can be a useful tool for the rapid classification of a normal and altered capillaroscopy pattern. In addition, it allows one to quickly calculate the number of capillaries. In the future, the tool will be developed and will make it possible to obtain full imaging characteristics independent of the experience of the examiner.

简介:毛细管镜检查是一种简单的甲襞毛细血管成像方法,用于诊断系统性硬化症。然而,对毛细血管图像的评估是费时且主观的。这使得对不同医生评估的研究进行详细比较变得困难。本初步研究旨在验证用于自动毛细管计数和图像分类为正常或病理的软件。材料和方法:本研究基于对200张来自系统性硬化症或硬皮病谱系疾病患者和健康人群的毛细血管镜图像的评估。使用Dinolite MEDL4N Pro进行毛细管镜检查。每张图像都是手工分析的,并使用工作软件进行描述。神经网络的训练采用fast。ai库(基于PyTorch)。选取ResNet-34深度残差神经网络;在GPU优化(P5000 GPU)环境下,使用最先进的神经网络Darknet-YoloV3状态,与验证和测试集进行10次交叉验证。对于1 mm毛细管的计算,设计了附加检测机构。结果:将神经网络训练得到的结果与人工分析得到的结果进行比较。在正确与病理图像的分类中,自动工具相对于人工评估的敏感性为89.0%,特异性为89.4%,在验证中分别为89.0%和86.9%。对于1 mm内平均毛细血管数,在感兴趣区域内检测到的真实图像精度为96.48%。结论:用于全自动毛细管镜图像评估的试点软件可以作为快速分类正常和改变的毛细管镜模式的有用工具。此外,它允许人们快速计算毛细血管的数量。在未来,该工具将被开发,并将使其能够独立于审查员的经验获得完整的成像特征。
{"title":"Automatic assessment of nailfold capillaroscopy software: a pilot study.","authors":"Olga Elżbieta Brzezińska, Krzysztof Andrzej Rychlicki-Kicior, Joanna Samanta Makowska","doi":"10.5114/reum/194040","DOIUrl":"10.5114/reum/194040","url":null,"abstract":"<p><strong>Introduction: </strong>Capillaroscopy is a simple method of nailfold capillary imaging, used to diagnose diseases from the systemic sclerosis spectrum. However, the assessment of the capillary image is time-consuming and subjective. This makes it difficult to use for a detailed comparison of studies assessed by various physicians. This pilot study aimed to validate software used for automatic capillary counting and image classification as normal or pathological.</p><p><strong>Material and methods: </strong>The study was based on the assessment of 200 capillaroscopic images obtained from patients suffering from systemic sclerosis or scleroderma spectrum diseases and healthy people. Dinolite MEDL4N Pro was used to perform capillaroscopy. Each image was analysed manually and described using working software. The neural network was trained using the fast.ai library (based on PyTorch). The ResNet-34 deep residual neural network was chosen; 10-fold cross-validation with the validation and test set was performed, using the Darknet-YoloV3 state of the art neural network in a GPU-optimized (P5000 GPU) environment. For the calculation of 1 mm capillaries, an additional detection mechanism was designed.</p><p><strong>Results: </strong>The results obtained under neural network training were compared to the results obtained in manual analysis. The sensitivity of the automatic tool relative to manual assessment in classification of correct vs. pathological images was 89.0%, specificity 89.4% for the training group, in validation 89.0% and 86.9% respectively. For the average number of capillaries in 1 mm the precision of real images detected within the region of interest was 96.48%.</p><p><strong>Conclusions: </strong>The pilot software for fully automatic capillaroscopic image assessment can be a useful tool for the rapid classification of a normal and altered capillaroscopy pattern. In addition, it allows one to quickly calculate the number of capillaries. In the future, the tool will be developed and will make it possible to obtain full imaging characteristics independent of the experience of the examiner.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"346-350"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profiles of systemic lupus erythematosus patients with co-existing sickle cell disease: a coincidence or true association?
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-12-24 DOI: 10.5114/reum/195432
Hakeem Babatunde Olaosebikan, Etseoghena Igebu, Adebukola Khairat Orolu, Gbenga Joshua Odunlami, Ilo Azizat Bamisebi, Akin Dada, Ebele Uche, Olufemi Adelowo

Introduction: Systemic lupus erythematosus (SLE) and sickle cell disease (SCD) are distinct multisystemic diseases that commonly affect blacks. There are few reports of their co-existence in Western literature and a paucity of reports in Sub-Saharan Africa. Their co-existence is associated with diagnostic delay and treatment dilemmas. The aim is to describe the clinical, laboratory, and treatment profile of Nigerian lupus with sickle cell disease.

Material and methods: A 7-year retrospective descriptive study of lupus patients with sickle cell disease was performed. Medical records of eligible patients were extracted into a proforma, transferred into SPSS, and analyzed with descriptive statistics. Sociodemographic, clinical, laboratory, and treatment data were presented as frequency and percentages.

Results: Twelve SLE-SCD cases (female 11, male 1) were identified. The mean age was 28.5 years and the mean duration of illness prior to diagnosis was 9.5 years. The median follow-up period was 3.1 years and the common presentations were mucocutaneous (66%), renal, (50%) serositis (33%), and neurological (16%) in decreasing order. All had anemia and positive antinuclear antibody, 33% had pancytopenia and 75% had positive anti-dsDNA and anti-Smith. Two are on maintenance hemodialysis, one with interstitial lung disease, and one on long-term anticoagulation due to deep vein thrombosis.

Conclusions: Sickle cell disease and SLE should be considered in SCD with atypical clinical and laboratory features. We hope this report will raise diagnostic suspicion and prompt early diagnosis and treatment to prevent multiorgan damage that may ensue from such an association.

{"title":"Profiles of systemic lupus erythematosus patients with co-existing sickle cell disease: a coincidence or true association?","authors":"Hakeem Babatunde Olaosebikan, Etseoghena Igebu, Adebukola Khairat Orolu, Gbenga Joshua Odunlami, Ilo Azizat Bamisebi, Akin Dada, Ebele Uche, Olufemi Adelowo","doi":"10.5114/reum/195432","DOIUrl":"10.5114/reum/195432","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic lupus erythematosus (SLE) and sickle cell disease (SCD) are distinct multisystemic diseases that commonly affect blacks. There are few reports of their co-existence in Western literature and a paucity of reports in Sub-Saharan Africa. Their co-existence is associated with diagnostic delay and treatment dilemmas. The aim is to describe the clinical, laboratory, and treatment profile of Nigerian lupus with sickle cell disease.</p><p><strong>Material and methods: </strong>A 7-year retrospective descriptive study of lupus patients with sickle cell disease was performed. Medical records of eligible patients were extracted into a proforma, transferred into SPSS, and analyzed with descriptive statistics. Sociodemographic, clinical, laboratory, and treatment data were presented as frequency and percentages.</p><p><strong>Results: </strong>Twelve SLE-SCD cases (female 11, male 1) were identified. The mean age was 28.5 years and the mean duration of illness prior to diagnosis was 9.5 years. The median follow-up period was 3.1 years and the common presentations were mucocutaneous (66%), renal, (50%) serositis (33%), and neurological (16%) in decreasing order. All had anemia and positive antinuclear antibody, 33% had pancytopenia and 75% had positive anti-dsDNA and anti-Smith. Two are on maintenance hemodialysis, one with interstitial lung disease, and one on long-term anticoagulation due to deep vein thrombosis.</p><p><strong>Conclusions: </strong>Sickle cell disease and SLE should be considered in SCD with atypical clinical and laboratory features. We hope this report will raise diagnostic suspicion and prompt early diagnosis and treatment to prevent multiorgan damage that may ensue from such an association.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 6","pages":"430-438"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reumatologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1